FRESCO-2: Fruquintinib in Patients with Refractory Metastati

Arvind N. Dasari, MD, MS, provides a comprehensive overview of the FRESCO-2 trial investigating fruquintinib in patients with refractory metastatic colorectal cancer.

Related Keywords

, Adverse Event Management , Colorectal Cancer , Optimizing Treatment Approaches , Refractory Metastatic , Crc , Colorectal Cancer Treatment , Mcrc Treatment , Fresco 2 , Fruquintinib , Refractory Colorectal Cancer , Refractory Crc , Bevacizumab , Immunotherapy , Tas 102 , Regorafenib , Safety Profile , Toxicity , Sunlight Trial ,